CVS Health released research indicating that while GLP-1 medications improve clinical outcomes and reduce medical spending, these savings do not currently offset their high pharmacy costs. This highlights a significant challenge for healthcare payers and could influence future formulary decisions and pricing negotiations.
CVS Health published a study using Aetna claims data on GLP-1 medications, finding that while they improve patient outcomes and reduce medical spending, these savings do not fully cover the high pharmacy costs at current market prices. This matters because it directly addresses the economic viability of widespread GLP-1 adoption for employers and health plans, which are key clients for CVS's PBM and insurance arms. The findings suggest continued pressure on GLP-1 manufacturers (like Eli Lilly and Novo Nordisk) regarding pricing, as payers (like UnitedHealth and Humana) seek to manage costs. In the short term, this reinforces the debate around GLP-1 affordability. Long-term, it could lead to more aggressive formulary management, increased rebate negotiations, or even pressure for legislative action on drug pricing, creating a key risk for pharmaceutical companies reliant on these drugs for growth.